JP6037597B2 - 遺伝子疾患および障害を治療するための間葉系幹細胞の使用 - Google Patents
遺伝子疾患および障害を治療するための間葉系幹細胞の使用 Download PDFInfo
- Publication number
- JP6037597B2 JP6037597B2 JP2010549663A JP2010549663A JP6037597B2 JP 6037597 B2 JP6037597 B2 JP 6037597B2 JP 2010549663 A JP2010549663 A JP 2010549663A JP 2010549663 A JP2010549663 A JP 2010549663A JP 6037597 B2 JP6037597 B2 JP 6037597B2
- Authority
- JP
- Japan
- Prior art keywords
- gene
- stem cells
- mesenchymal stem
- pharmaceutical composition
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 210000002901 mesenchymal stem cell Anatomy 0.000 title claims description 269
- 208000026350 Inborn Genetic disease Diseases 0.000 title description 40
- 208000016361 genetic disease Diseases 0.000 title description 40
- 210000001519 tissue Anatomy 0.000 claims description 67
- 108090000623 proteins and genes Proteins 0.000 claims description 61
- 210000004027 cell Anatomy 0.000 claims description 50
- 239000008194 pharmaceutical composition Substances 0.000 claims description 24
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 21
- 210000002798 bone marrow cell Anatomy 0.000 claims description 18
- 210000001185 bone marrow Anatomy 0.000 claims description 17
- 102000004169 proteins and genes Human genes 0.000 claims description 15
- 108010069091 Dystrophin Proteins 0.000 claims description 14
- 230000037396 body weight Effects 0.000 claims description 13
- 238000001990 intravenous administration Methods 0.000 claims description 13
- 102000001039 Dystrophin Human genes 0.000 claims description 12
- 102000004547 Glucosylceramidase Human genes 0.000 claims description 9
- 108010017544 Glucosylceramidase Proteins 0.000 claims description 9
- 230000000735 allogeneic effect Effects 0.000 claims description 8
- 108010032963 Ataxin-1 Proteins 0.000 claims description 6
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 6
- 101150113725 hd gene Proteins 0.000 claims description 5
- 101150075644 ATP7B gene Proteins 0.000 claims description 4
- 101150029409 CFTR gene Proteins 0.000 claims description 4
- 101150062966 FBN1 gene Proteins 0.000 claims description 3
- 101100029888 Homo sapiens PKD1 gene Proteins 0.000 claims description 3
- 101001000631 Homo sapiens Peripheral myelin protein 22 Proteins 0.000 claims description 3
- 101001082860 Homo sapiens Peroxisomal membrane protein 2 Proteins 0.000 claims description 3
- 101150056230 PKD1 gene Proteins 0.000 claims description 3
- 102100030564 Peroxisomal membrane protein 2 Human genes 0.000 claims description 3
- 108091006277 SLC5A1 Proteins 0.000 claims description 3
- 101150004834 Wrn gene Proteins 0.000 claims description 3
- 101150049512 ald gene Proteins 0.000 claims description 3
- 101150062190 sod1 gene Proteins 0.000 claims description 3
- 101150092724 CLCN7 gene Proteins 0.000 claims description 2
- 101100518492 Homo sapiens OSTM1 gene Proteins 0.000 claims description 2
- 101150046588 OSTM1 gene Proteins 0.000 claims description 2
- 101150032738 TCIRG1 gene Proteins 0.000 claims description 2
- 101150010487 are gene Proteins 0.000 claims description 2
- 230000002629 repopulating effect Effects 0.000 claims description 2
- 210000004271 bone marrow stromal cell Anatomy 0.000 claims 2
- 238000005516 engineering process Methods 0.000 description 43
- 238000000034 method Methods 0.000 description 32
- 241001465754 Metazoa Species 0.000 description 30
- 238000012384 transportation and delivery Methods 0.000 description 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 28
- 201000010099 disease Diseases 0.000 description 26
- 238000011282 treatment Methods 0.000 description 20
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 18
- 201000003883 Cystic fibrosis Diseases 0.000 description 16
- 230000006870 function Effects 0.000 description 14
- 210000004072 lung Anatomy 0.000 description 13
- 210000003205 muscle Anatomy 0.000 description 13
- 210000000056 organ Anatomy 0.000 description 13
- 208000024891 symptom Diseases 0.000 description 13
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 11
- 206010061218 Inflammation Diseases 0.000 description 11
- 208000018839 Wilson disease Diseases 0.000 description 11
- 230000002757 inflammatory effect Effects 0.000 description 11
- 230000004054 inflammatory process Effects 0.000 description 11
- 230000035772 mutation Effects 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- 208000018737 Parkinson disease Diseases 0.000 description 10
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 10
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 description 9
- 208000015872 Gaucher disease Diseases 0.000 description 9
- 210000004556 brain Anatomy 0.000 description 9
- 230000005012 migration Effects 0.000 description 9
- 238000013508 migration Methods 0.000 description 9
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 8
- 238000009825 accumulation Methods 0.000 description 8
- 229910052802 copper Inorganic materials 0.000 description 8
- 239000010949 copper Substances 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 210000002569 neuron Anatomy 0.000 description 8
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 7
- 230000009395 genetic defect Effects 0.000 description 7
- 208000024827 Alzheimer disease Diseases 0.000 description 6
- 208000023105 Huntington disease Diseases 0.000 description 6
- 238000001802 infusion Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 5
- 108090001061 Insulin Proteins 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 5
- 102000003802 alpha-Synuclein Human genes 0.000 description 5
- 108090000185 alpha-Synuclein Proteins 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000002950 deficient Effects 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 230000003176 fibrotic effect Effects 0.000 description 5
- 230000028709 inflammatory response Effects 0.000 description 5
- 229940125396 insulin Drugs 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 210000000663 muscle cell Anatomy 0.000 description 5
- 230000004770 neurodegeneration Effects 0.000 description 5
- 230000002688 persistence Effects 0.000 description 5
- 238000011552 rat model Methods 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000002054 transplantation Methods 0.000 description 5
- 102100024643 ATP-binding cassette sub-family D member 1 Human genes 0.000 description 4
- 201000011452 Adrenoleukodystrophy Diseases 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 206010064571 Gene mutation Diseases 0.000 description 4
- 102000008100 Human Serum Albumin Human genes 0.000 description 4
- 108091006905 Human Serum Albumin Proteins 0.000 description 4
- 208000004852 Lung Injury Diseases 0.000 description 4
- 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 description 4
- 206010069363 Traumatic lung injury Diseases 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 231100000515 lung injury Toxicity 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- 210000000496 pancreas Anatomy 0.000 description 4
- 230000000750 progressive effect Effects 0.000 description 4
- 102000019034 Chemokines Human genes 0.000 description 3
- 108010012236 Chemokines Proteins 0.000 description 3
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000001363 autoimmune Effects 0.000 description 3
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000010322 bone marrow transplantation Methods 0.000 description 3
- 210000004958 brain cell Anatomy 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 210000000963 osteoblast Anatomy 0.000 description 3
- 208000002865 osteopetrosis Diseases 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 230000007115 recruitment Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 230000000451 tissue damage Effects 0.000 description 3
- 231100000827 tissue damage Toxicity 0.000 description 3
- 102100024321 Alkaline phosphatase, placental type Human genes 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- 102000007372 Ataxin-1 Human genes 0.000 description 2
- 102000014461 Ataxins Human genes 0.000 description 2
- 108010078286 Ataxins Proteins 0.000 description 2
- 201000006935 Becker muscular dystrophy Diseases 0.000 description 2
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 2
- 206010008025 Cerebellar ataxia Diseases 0.000 description 2
- 206010053684 Cerebrohepatorenal syndrome Diseases 0.000 description 2
- YBSQGNFRWZKFMJ-UHFFFAOYSA-N Cerebroside B Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=C(C)CCCCCCCCC)COC1OC(CO)C(O)C(O)C1O YBSQGNFRWZKFMJ-UHFFFAOYSA-N 0.000 description 2
- 108091004554 Copper Transport Proteins Proteins 0.000 description 2
- 102000020856 Copper Transport Proteins Human genes 0.000 description 2
- 102000012437 Copper-Transporting ATPases Human genes 0.000 description 2
- 102100023419 Cystic fibrosis transmembrane conductance regulator Human genes 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 208000011345 Duchenne and Becker muscular dystrophy Diseases 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000001826 Marfan syndrome Diseases 0.000 description 2
- 208000008948 Menkes Kinky Hair Syndrome Diseases 0.000 description 2
- 208000012583 Menkes disease Diseases 0.000 description 2
- 108010083674 Myelin Proteins Proteins 0.000 description 2
- 102000006386 Myelin Proteins Human genes 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 102100022033 Presenilin-1 Human genes 0.000 description 2
- 108010036933 Presenilin-1 Proteins 0.000 description 2
- 102100022036 Presenilin-2 Human genes 0.000 description 2
- 108010036908 Presenilin-2 Proteins 0.000 description 2
- 208000032536 Pseudomonas Infections Diseases 0.000 description 2
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 2
- 108010021188 Superoxide Dismutase-1 Proteins 0.000 description 2
- 102100038836 Superoxide dismutase [Cu-Zn] Human genes 0.000 description 2
- 201000011032 Werner Syndrome Diseases 0.000 description 2
- 201000004525 Zellweger Syndrome Diseases 0.000 description 2
- 208000036813 Zellweger spectrum disease Diseases 0.000 description 2
- 238000002679 ablation Methods 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 2
- 229960001736 buprenorphine Drugs 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 101150002195 cmt gene Proteins 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000003412 degenerative effect Effects 0.000 description 2
- 238000002716 delivery method Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 210000004700 fetal blood Anatomy 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000001476 gene delivery Methods 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 208000005594 glucose-galactose malabsorption Diseases 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000000777 hematopoietic system Anatomy 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000004558 lewy body Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000004199 lung function Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000002161 motor neuron Anatomy 0.000 description 2
- 201000006938 muscular dystrophy Diseases 0.000 description 2
- 230000000869 mutational effect Effects 0.000 description 2
- 210000005012 myelin Anatomy 0.000 description 2
- 210000000107 myocyte Anatomy 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 230000016273 neuron death Effects 0.000 description 2
- 210000002997 osteoclast Anatomy 0.000 description 2
- 210000000578 peripheral nerve Anatomy 0.000 description 2
- 108010031345 placental alkaline phosphatase Proteins 0.000 description 2
- 208000030761 polycystic kidney disease Diseases 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 208000002320 spinal muscular atrophy Diseases 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 210000002303 tibia Anatomy 0.000 description 2
- 238000011277 treatment modality Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 101150101112 7 gene Proteins 0.000 description 1
- 101150100395 ALS1 gene Proteins 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 101100284398 Bos taurus BoLA-DQB gene Proteins 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 108010075016 Ceruloplasmin Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 102000000018 Chemokine CCL2 Human genes 0.000 description 1
- 108010062745 Chloride Channels Proteins 0.000 description 1
- 102000011045 Chloride Channels Human genes 0.000 description 1
- 208000026372 Congenital cystic kidney disease Diseases 0.000 description 1
- 102100027591 Copper-transporting ATPase 2 Human genes 0.000 description 1
- 102000012605 Cystic Fibrosis Transmembrane Conductance Regulator Human genes 0.000 description 1
- 208000026292 Cystic Kidney disease Diseases 0.000 description 1
- 208000013558 Developmental Bone disease Diseases 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101000936280 Homo sapiens Copper-transporting ATPase 2 Proteins 0.000 description 1
- 101000613806 Homo sapiens Osteopetrosis-associated transmembrane protein 1 Proteins 0.000 description 1
- 101001100327 Homo sapiens RNA-binding protein 45 Proteins 0.000 description 1
- 108010057081 Merozoite Surface Protein 1 Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 206010031243 Osteogenesis imperfecta Diseases 0.000 description 1
- 102100040559 Osteopetrosis-associated transmembrane protein 1 Human genes 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102100038823 RNA-binding protein 45 Human genes 0.000 description 1
- 208000019155 Radiation injury Diseases 0.000 description 1
- 206010040030 Sensory loss Diseases 0.000 description 1
- 206010072610 Skeletal dysplasia Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 206010047897 Weight gain poor Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001766 X chromosome Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000006505 cellular lipid metabolism Effects 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000037416 cystogenesis Effects 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 210000004002 dopaminergic cell Anatomy 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000004970 emotional disturbance Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 210000003811 finger Anatomy 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 102000054767 gene variant Human genes 0.000 description 1
- -1 gene variants Proteins 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000004247 hand Anatomy 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000005550 inflammation mediator Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 238000011694 lewis rat Methods 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000005499 meniscus Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000005088 multinucleated cell Anatomy 0.000 description 1
- 230000004220 muscle function Effects 0.000 description 1
- 230000023105 myelination Effects 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 210000004417 patella Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000002824 peroxisome Anatomy 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 210000004116 schwann cell Anatomy 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000002955 secretory cell Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 238000013125 spirometry Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000009092 tissue dysfunction Effects 0.000 description 1
- 230000008427 tissue turnover Effects 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Neurosurgery (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/042,487 US20080286249A1 (en) | 2006-01-12 | 2008-03-05 | Use of mesenchymal stem cells for treating genetic diseases and disorders |
| US12/042,487 | 2008-03-05 | ||
| PCT/US2009/001390 WO2009111030A1 (en) | 2008-03-05 | 2009-03-04 | Use of mesenchymal stem cells for treating genetic diseases and disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011514901A JP2011514901A (ja) | 2011-05-12 |
| JP2011514901A5 JP2011514901A5 (https=) | 2012-04-19 |
| JP6037597B2 true JP6037597B2 (ja) | 2016-12-07 |
Family
ID=40635808
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010549663A Expired - Fee Related JP6037597B2 (ja) | 2008-03-05 | 2009-03-04 | 遺伝子疾患および障害を治療するための間葉系幹細胞の使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (8) | US20080286249A1 (https=) |
| EP (1) | EP2262513A1 (https=) |
| JP (1) | JP6037597B2 (https=) |
| CN (1) | CN102014936A (https=) |
| AU (1) | AU2009220137A1 (https=) |
| BR (1) | BRPI0909817A2 (https=) |
| CA (1) | CA2717498A1 (https=) |
| MX (1) | MX2010009767A (https=) |
| NZ (1) | NZ587809A (https=) |
| WO (1) | WO2009111030A1 (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2471907T3 (pl) | 2005-12-29 | 2019-07-31 | Celularity, Inc. | Populacje komórek macierzystych łożyska |
| KR20200011604A (ko) | 2008-08-20 | 2020-02-03 | 안트로제네시스 코포레이션 | 개선된 세포 조성물 및 그의 제조 방법 |
| CA2734446C (en) | 2008-08-22 | 2017-06-20 | Anthrogenesis Corporation | Methods and compositions for treatment of bone defects with placental cell populations |
| RU2539786C2 (ru) | 2008-09-02 | 2015-01-27 | Плуристем Лтд. | Выращенные в прикрепленной к субстрату культуре клетки из ткани плаценты и их использование при лечении |
| RU2015130665A (ru) | 2008-11-19 | 2018-12-24 | Антродженезис Корпорейшн | Амниотические адгезивные клетки |
| WO2011064733A1 (en) * | 2009-11-27 | 2011-06-03 | Stempeutics Research Pvt. Ltd. | Methods of preparing mesenchymal stem cells, compositions and kit thereof |
| US20110142805A1 (en) * | 2009-12-15 | 2011-06-16 | Advanced Technologies And Regenerative Medicine, Llc | Method of renal repair and regeneration and the treatment of diabetic nephropathy |
| EP2555783A1 (en) | 2010-04-08 | 2013-02-13 | Anthrogenesis Corporation | Treatment of sarcoidosis using placental stem cells |
| WO2012092485A1 (en) | 2010-12-31 | 2012-07-05 | Anthrogenesis Corporation | Enhancement of placental stem cell potency using modulatory rna molecules |
| KR101903339B1 (ko) * | 2011-03-22 | 2018-10-01 | 플루리스템 리미티드 | 방사선 또는 화학적 손상을 치료하는 방법 |
| ES2707579T3 (es) | 2011-06-01 | 2019-04-04 | Celularity Inc | Tratamiento del dolor usando citoblastos placentarios |
| WO2013055476A1 (en) * | 2011-09-09 | 2013-04-18 | Anthrogenesis Corporation | Treatment of amyotrophic lateral sclerosis using placental stem cells |
| CN103183736A (zh) * | 2011-12-27 | 2013-07-03 | 北京和信非凡生物技术有限公司 | 一种抗clcn7蛋白的单克隆抗体及其应用 |
| KR20150065697A (ko) * | 2012-09-04 | 2015-06-15 | 안트로제네시스 코포레이션 | 조직 생성 방법 |
| WO2014087658A1 (en) * | 2012-12-07 | 2014-06-12 | Kuraray Co., Ltd. | Method of cell fusion and fusion cells |
| US20140271568A1 (en) | 2013-03-12 | 2014-09-18 | Hawking Biological Technology Co., Ltd | Method and kit for providing an increased expression of telomerase, brain-derived neurotrophic factor, stromal cell-derived factor-1, cxc chemokine receptor 4, and/or immune regulatory factor of stem cell |
| CN104042606B (zh) * | 2013-03-12 | 2017-05-24 | 国钦生物科技股份有限公司 | 苯酞化合物的应用 |
| EP3151847B1 (en) * | 2014-06-04 | 2020-07-29 | Cedars-Sinai Medical Center | Human mesenchymal stem cells and pth for use in a method for non surgical repair of vertebral compression fractures |
| CN104726496B (zh) * | 2015-03-27 | 2017-07-07 | 中国科学院生物物理研究所 | 携带人类成年早衰症基因突变的多能干细胞及制备方法 |
| JP6890553B2 (ja) * | 2015-06-11 | 2021-06-18 | ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイＴｈｅ Ｂｏａｒｄ Ｏｆ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｉｌｌｉｎｏｉｓ | 筋ジストロフィーキメラ細胞および筋ジストロフィーの処置方法 |
| US10596298B2 (en) | 2016-04-22 | 2020-03-24 | Vivex Biologics Group, Inc. | Malleable demineralized bone composition and method of manufacture |
| US11253629B2 (en) | 2016-04-22 | 2022-02-22 | Vivex Biologics Group, Inc. | Bone gel sheet composition and method of manufacture |
| US10463767B2 (en) | 2016-04-22 | 2019-11-05 | Vivex Biologics Group, Inc. | Moldable bone composition |
| US9788950B1 (en) | 2016-04-22 | 2017-10-17 | Vivex Biomedical, Inc. | Cohesive bone composition |
| US11253630B2 (en) | 2016-04-22 | 2022-02-22 | Vivex Biologics Group, Inc. | Malleable demineralized bone composition and method of manufacture |
| WO2018092769A1 (ja) | 2016-11-15 | 2018-05-24 | 株式会社カネカ | 胎児付属物に由来する間葉系幹細胞を含む細胞集団とその製造方法、及び医薬組成物 |
| CN111406106A (zh) * | 2017-11-28 | 2020-07-10 | 伊利诺伊大学理事会 | 多嵌合细胞以及移植疗法与免疫缺陷和遗传病症的治疗 |
| WO2019132026A1 (ja) | 2017-12-28 | 2019-07-04 | 株式会社カネカ | 接着性幹細胞を含む細胞集団とその製造方法、及び医薬組成物 |
| WO2020251020A1 (ja) | 2019-06-14 | 2020-12-17 | 株式会社カネカ | 間葉系細胞を含む細胞集団、それを含む医薬組成物、及び、その製造方法 |
| WO2024183769A1 (en) * | 2023-03-06 | 2024-09-12 | Lingyi Biotech Co., Ltd. | A truncated atp7b and the use thereof |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5733542A (en) * | 1990-11-16 | 1998-03-31 | Haynesworth; Stephen E. | Enhancing bone marrow engraftment using MSCS |
| US5486359A (en) * | 1990-11-16 | 1996-01-23 | Osiris Therapeutics, Inc. | Human mesenchymal stem cells |
| US6010696A (en) * | 1990-11-16 | 2000-01-04 | Osiris Therapeutics, Inc. | Enhancing hematopoietic progenitor cell engraftment using mesenchymal stem cells |
| US5635156A (en) * | 1993-09-13 | 1997-06-03 | University Of Pittsburgh | Non-lethal methods for conditioning a recipient for bone marrow transplantation |
| US5591625A (en) * | 1993-11-24 | 1997-01-07 | Case Western Reserve University | Transduced mesenchymal stem cells |
| US6653134B2 (en) * | 1995-03-28 | 2003-11-25 | Cp Hahnemann University | Isolated stromal cells for use in the treatment of diseases of the central nervous system |
| US6974571B2 (en) * | 1995-03-28 | 2005-12-13 | Thomas Jefferson University | Isolated stromal cells and methods of using the same |
| US6962698B1 (en) * | 1998-02-17 | 2005-11-08 | Gamida Cell Ltd. | Methods of controlling proliferation and differentiation of stem and progenitor cells |
| AU749675B2 (en) * | 1998-03-13 | 2002-07-04 | Mesoblast International Sarl | Uses for human non-autologous mesenchymal stem cells |
| AU755888B2 (en) * | 1998-03-18 | 2003-01-02 | Mesoblast International Sarl | Mesenchymal stem cells for prevention and treatment of immune responses in transplantation |
| US7544509B2 (en) * | 2000-01-24 | 2009-06-09 | Mcgill University | Method for preparing stem cell preparations |
| JPWO2003014336A1 (ja) * | 2001-08-07 | 2004-11-25 | 麒麟麦酒株式会社 | 造血幹細胞の製造法 |
| CA2460985C (en) * | 2001-09-20 | 2016-01-05 | Anticancer, Inc. | Nestin-expressing hair follicle stem cells |
| US20050048036A1 (en) * | 2001-12-07 | 2005-03-03 | Hedrick Marc H. | Methods of using regenerative cells in the treatment of inherited and acquired disorders of the bone, bone marrow, liver, and other tissues |
| US20030157110A1 (en) * | 2002-01-07 | 2003-08-21 | Millennium Pharmaceuticals, Inc. | Methods for the treatment of metabolic disorders, including obesity and diabetes |
| ATE421328T1 (de) * | 2002-02-22 | 2009-02-15 | Intracel Recources Llc | Sterile immunogene nicht-tumorigene tumorzell- zusammensetzungen und verfahren |
| US20050058641A1 (en) * | 2002-05-22 | 2005-03-17 | Siemionow Maria Z. | Tolerance induction and maintenance in hematopoietic stem cell allografts |
| DE10242337A1 (de) * | 2002-09-09 | 2004-03-18 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Antikörper zur Isolierung und/oder Identifizierung neuronaler Stammzellen und Verfahren zur Isolierung und/oder Identifizierung neuronaler Vorläuferzellen |
| GB0304030D0 (en) * | 2003-02-21 | 2003-03-26 | King S College London | Teeth |
| JP2007535486A (ja) * | 2003-05-07 | 2007-12-06 | ラ ホーヤ インスティチュート フォー モレキュラー メディシン | 高分子量のヒアルロン酸を用いた内因性又は埋め込まれた又は移植された幹細胞の機能回復を促進するための方法 |
| US20050019801A1 (en) * | 2003-06-04 | 2005-01-27 | Curis, Inc. | Stem cell-based methods for identifying and characterizing agents |
| EP2399990B1 (en) * | 2003-06-27 | 2015-07-22 | DePuy Synthes Products, Inc. | Cells derived from post-partum umbilical cord for use in treatment of disease of the heart and circulatory system |
| US20050256077A1 (en) * | 2004-03-30 | 2005-11-17 | Henning Susan J | Gastrointestinal stem cells and uses thereof |
| US20070253931A1 (en) * | 2006-01-12 | 2007-11-01 | Osiris Therapeutics, Inc. | Use of mesenchymal stem cells for treating genetic diseases and disorders |
-
2008
- 2008-03-05 US US12/042,487 patent/US20080286249A1/en not_active Abandoned
-
2009
- 2009-03-04 EP EP09717978A patent/EP2262513A1/en not_active Withdrawn
- 2009-03-04 CN CN2009801155331A patent/CN102014936A/zh active Pending
- 2009-03-04 AU AU2009220137A patent/AU2009220137A1/en not_active Abandoned
- 2009-03-04 JP JP2010549663A patent/JP6037597B2/ja not_active Expired - Fee Related
- 2009-03-04 BR BRPI0909817A patent/BRPI0909817A2/pt not_active IP Right Cessation
- 2009-03-04 NZ NZ587809A patent/NZ587809A/xx not_active IP Right Cessation
- 2009-03-04 WO PCT/US2009/001390 patent/WO2009111030A1/en not_active Ceased
- 2009-03-04 MX MX2010009767A patent/MX2010009767A/es active IP Right Grant
- 2009-03-04 CA CA2717498A patent/CA2717498A1/en not_active Abandoned
-
2010
- 2010-07-28 US US12/845,191 patent/US20100291047A1/en not_active Abandoned
- 2010-09-02 US US12/874,796 patent/US20100330052A1/en not_active Abandoned
-
2011
- 2011-03-31 US US13/077,004 patent/US20110177045A1/en not_active Abandoned
-
2012
- 2012-06-29 US US13/538,198 patent/US20120263687A1/en not_active Abandoned
-
2013
- 2013-01-03 US US13/733,550 patent/US20130121975A1/en not_active Abandoned
- 2013-07-26 US US13/951,685 patent/US20140030235A1/en not_active Abandoned
-
2014
- 2014-07-14 US US14/330,084 patent/US20140322180A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20140030235A1 (en) | 2014-01-30 |
| EP2262513A1 (en) | 2010-12-22 |
| US20100330052A1 (en) | 2010-12-30 |
| NZ587809A (en) | 2012-08-31 |
| US20130121975A1 (en) | 2013-05-16 |
| WO2009111030A1 (en) | 2009-09-11 |
| BRPI0909817A2 (pt) | 2017-06-13 |
| US20100291047A1 (en) | 2010-11-18 |
| CN102014936A (zh) | 2011-04-13 |
| US20120263687A1 (en) | 2012-10-18 |
| AU2009220137A1 (en) | 2009-09-11 |
| US20080286249A1 (en) | 2008-11-20 |
| CA2717498A1 (en) | 2009-09-11 |
| US20140322180A1 (en) | 2014-10-30 |
| JP2011514901A (ja) | 2011-05-12 |
| US20110177045A1 (en) | 2011-07-21 |
| MX2010009767A (es) | 2010-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6037597B2 (ja) | 遺伝子疾患および障害を治療するための間葉系幹細胞の使用 | |
| AU2013205951B2 (en) | Use of mesenchymal stem cells for treating genetic diseases and disorders | |
| KR20140048840A (ko) | 초음파 캐비테이션 유도된 간질 또는 간엽 혈관 추출물 및 이로부터 유도되고 아디포스 조직으로부터 수득된 세포 및 이의 용도 | |
| Mohammedsaleh | The use of patient-specific stem cells in different autoimmune diseases | |
| Kizilay et al. | Effect of systemic application of bone marrow-derived mesenchymal stem cells on healing of peripheral nerve injury in an experimental sciatic nerve injury model | |
| Aejaz et al. | Stem cell therapy—Present status | |
| Hekmatnejad et al. | Transplantation to study satellite cell heterogeneity in skeletal muscle | |
| Stoltz et al. | Cell and tissue engineering and clinical applications: an overview | |
| Köse et al. | Stem cell applications in lysosomal storage disorders: progress and ongoing challenges | |
| KR101577553B1 (ko) | 중간엽 줄기 세포 및 그에 대한 용도 | |
| AU2015201881A1 (en) | Use of mesenchymal stem cells for treating genetic diseases and disorders | |
| Xiong et al. | Microdystrophin delivery in dystrophin-deficient (mdx) mice by genetically-corrected syngeneic MSCs transplantation | |
| EP3890756B1 (en) | Indirect ultrasonic cavitation-derived perivascular cells and methods of use thereof | |
| Eve | The continued promise of stem cell therapy in regenerative medicine | |
| Ripoll | Adult stem cell therapy in the twitcher mouse model of Krabbe's disease utilizing mesenchymal lineage stem cells | |
| an Experimental | Potently Immunosuppressive 5-Fluorouracil | |
| Queiri | Stem Cell Therapy for Muscular Dystrophy 2020 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120305 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120305 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130813 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20131113 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20131120 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140213 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20140314 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140325 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140804 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160509 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160608 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160708 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160809 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20161101 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6037597 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |